AstraZeneca reveals mixed interim findings in lung cancer tr

AstraZeneca announced on Monday that datopotamab deruxtecan, or ‘Dato-DXd’, has shown promising results in a trial in patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) who had previously received at least one therapy.

Related Keywords

Daiichi Sankyo , Susan Galbraith , Astrazeneca , Reveals , Mixed , Interim , Findings , Lung , Cancer , Trial , Category All , Category Market Report , Category Company News , Category News And Announcements , Category Market Pulse , Category Headline News , Category Sectorial Health Technology , Mostread All , Mostread Company News ,